Cargando…
Are HIV positive patients resistant to statin therapy?
BACKGROUND: Patients with HIV are subject to development of HIV metabolic syndrome characterized by dyslipidemia, lipodystrophy and insulin resistance secondary to highly active antiretroviral therapy (HAART). Rosuvastatin is a highly potent HMG-CoA reductase inhibitor. Rosuvastatin is effective at...
Autores principales: | Johns, Kevin W, Bennett, Matthew T, Bondy, Gregory P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2186312/ https://www.ncbi.nlm.nih.gov/pubmed/17958912 http://dx.doi.org/10.1186/1476-511X-6-27 |
Ejemplares similares
-
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
por: Bennett, Matthew T, et al.
Publicado: (2007) -
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015) -
Statin therapy, myopathy and exercise--a case report
por: Semple, Stuart J
Publicado: (2012) -
Delays in antiretroviral therapy initiation among HIV-positive individuals: results of the positive living with HIV study
por: Poudel, Krishna C., et al.
Publicado: (2016) -
Statin Therapy and Vascular Inflammation Detected by Positron Emission Tomography/Computed Tomography in Patients with Psoriasis
por: KAISER, Hannah, et al.
Publicado: (2021)